Managed Care Review Board™ Presents: Managed Care Considerations on the Emerging Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma

Learn About:

• Current evidence-based recommendations for the treatment of NHL
• The burdens of relapsed/refractory follicular lymphoma
• How reimbursement policies can be developed to align with broader goals to reduce NHL morbidity and mortality

Expert Faculty Presenters

P. Connor Johnson, MD Attending Oncologist Massachusetts General Hospital Center for Lymphoma Click here for biography Ryan Haumschild, PharmD, MS, MBA Director of Pharmacy Services Emory Healthcare and Winship Cancer Institute Click here for biography Gary M. Owens, MD President Gary Owens Associates, Inc. Click here for biography Fadia T. Shaya, PhD, MPH, FAMIA Distinguished University Professor Population Health and Data Science Executive Director, Behavioral Health Resources and Technical Assistance Program Department of Practice, Sciences, and Health Outcomes Research University of Maryland School of Pharmacy Co-Director of Informatics - Innovation, Dissemination, and Implementation Institute for Clinical and Translational Research University of Maryland Baltimore Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
The expanding array of therapeutic strategies for Non-Hodgkin's Lymphoma (NHL) poses an ongoing challenge in optimal treatment selection and sequencing. Despite notable advancements in disease management and patient survival, many individuals still face disease relapse or encounter treatment-limiting toxicities. Bispecific antibodies (BsAbs) employ elements from diverse antibodies to offer targeted therapeutic approaches, particularly for hematologic malignancies like lymphomas. As clinical evidence supporting the use of BsAbs in hematologic malignancies continues to emerge, managed care pharmacists will need to identify formulary and utilization management strategies that effectively incorporate BsAbs into the current treatment armamentarium. Leverage the expertise of this interactive multistakeholder panel discussion to understand the role of emerging innovative treatments, optimize outcomes, and enhance the care of patients with relapsed/refractory NHL.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe current evidence-based recommendations for the treatment of Non-Hodgkin's Lymphoma (NHL)
• Explore the structural properties, clinical benefits, and safety of bispecific antibodies (BsAbs) for patients with relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
• Analyze clinical trial data to clarify the place in therapy for BsAbs in the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
• Describe the burdens of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma on patients
• Assess how reimbursement policies can be developed to align with broader goals to reduce NHL morbidity and mortality

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-077-L01-P
Activity Type: Knowledge-based

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.
Please note: Registration for AMCP 2024 is NOT required to attend this symposium.